Seeking Alpha

Microcap biotech firm Neuralstem (CUR +0.6%) says the FDA has signed off for the company to...

Microcap biotech firm Neuralstem (CUR +0.6%) says the FDA has signed off for the company to advance to Phase Ib in the ongoing clinical trial of its novel neuroregenerative compound, NSI-189, for the treatment of major depressive disorder.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio:

|